These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27263239)

  • 41. [Company integration management in small and medium-sized companies. Legal requirements and prerequisites for successful implementation].
    Ramm D; Mahnke C; Tauscher A; Welti F; Seider H; Shafaei R
    Rehabilitation (Stuttg); 2012 Jan; 51(1):10-7. PubMed ID: 22311393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biotechnology software in the digital age: are you winning?
    Scheitz CJF; Peck LJ; Groban ES
    J Ind Microbiol Biotechnol; 2018 Jul; 45(7):529-534. PubMed ID: 29335911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. US biotechnology companies and foreign nationals: the changing dynamics of access to H-1B visas.
    Dahms AS; Trow SC
    Nat Biotechnol; 2005 May; 23(5):629-30. PubMed ID: 15877077
    [No Abstract]   [Full Text] [Related]  

  • 44. Researchers cut loose as Pfizer and Merck shutter European sites.
    Subbaraman N
    Nat Biotechnol; 2011 Apr; 29(4):299-300. PubMed ID: 21478836
    [No Abstract]   [Full Text] [Related]  

  • 45. Invention and business performance in the tissue-engineering industry.
    Pangarkar N; Hutmacher DW
    Tissue Eng; 2003 Dec; 9(6):1313-22. PubMed ID: 14670118
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Critical issues for effective collaboration between academia and industry in the field of regenerative medicine in Japan.
    Tsubouchi M; Morishita R; Tabata Y; Matsui S; Kawakami K
    Regen Med; 2008 Jul; 3(4):497-504. PubMed ID: 18588472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Understanding and Managing the Biotechnology Valley of Death.
    Linton JD; Xu W
    Trends Biotechnol; 2021 Feb; 39(2):107-110. PubMed ID: 32718779
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Academic industry relationships in biotechnology: a primer on policy and practice.
    Campbell EG; Blumenthal D
    Cloning; 2000; 2(3):129-36. PubMed ID: 16218849
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Do all types of restructuring threaten employees' well-being? An exploratory study.
    Widerszal-Bazyl M; Mockałło Z
    Int J Occup Med Environ Health; 2015; 28(4):689-706. PubMed ID: 26216308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PMDedu: Assessing the educational needs of startups and academic investigators focused on pediatric medical device development.
    Shah P; Snitman A; McCaney J; Rose LM; Sheridan D; Espinoza Salomon J
    J Clin Transl Sci; 2023; 7(1):e235. PubMed ID: 38028345
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Creating knowledge structures in the pharmaceutical industry: the increasing significance of virtual organisation.
    Salazar A; Howells J
    World Hosp Health Serv; 2000; 36(2):6-10, 44-5. PubMed ID: 11214458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The JIM interview. Art Levinson, PhD.
    Levinson A
    J Investig Med; 1997 Jun; 45(5):230-7. PubMed ID: 9249995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Create products by going virtual.
    Hogan J
    Med Device Technol; 2005 Nov; 16(9):38-9. PubMed ID: 16438448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Corporate preparedness for pandemic influenza: a survey of pharmaceutical and biotechnology companies in Montgomery County, Maryland.
    Watkins RJ; Barnett DJ; Links JM
    Biosecur Bioterror; 2008 Sep; 6(3):219-26. PubMed ID: 18795831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Future space. A new blueprint for business architecture.
    Huang J
    Harv Bus Rev; 2001 Apr; 79(4):149-58, 170. PubMed ID: 11299691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trade pact disappoints biotechnology companies and campaigners for better access to drugs.
    McCarthy M
    BMJ; 2015 Oct; 351():h5360. PubMed ID: 26443618
    [No Abstract]   [Full Text] [Related]  

  • 57. Industrial biotechnology in Japan--a cultural perspective.
    Bach WG
    Australas Biotechnol; 1994; 4(1):50-2. PubMed ID: 7764616
    [No Abstract]   [Full Text] [Related]  

  • 58. Biomaterials. New Chinese biochip center straddles business, academe.
    Yimin D
    Science; 2000 Dec; 290(5499):2061-2. PubMed ID: 11187827
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Business Entity Selection: Why It Matters to Healthcare Practitioners. Part II--Corporations, Limited Liability Companies, and Professional Entities.
    Nithman RW
    J Med Pract Manage; 2015; 30(6):377-80. PubMed ID: 26182701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Private sector development of stem cell technology and therapeutic cloning.
    Lysaght MJ; Hazlehurst AL
    Tissue Eng; 2003 Jun; 9(3):555-61. PubMed ID: 12857423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.